Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

June 14, 2017June 14, 2017

Aequus, Canada’s CDRD to Study Cannabinoid-based Therapeutics for Epilepsy, Other Disorders

News

Aequus Pharmaceuticals and the Canadian Centre for Drug Research and Development (CDRD) are collaborating in preclinical studies evaluating the safety and efficacy of cannabinoid-based products for epilepsy as well as ... Read more

June 12, 2017June 12, 2017

Epileptics, Others with Brain Damage Find Faces Looking Sideways More Memorable, U.K. Study Shows

News

Epilepsy patients and others with damage in a part of the brain called the amygdala fail to recognize facial emotions, though they find faces looking sideways more memorable, a new ... Read more

May 26, 2017May 26, 2017

Modified-Release Lacosamide, ADS-4101, Seen as Safe and Well-Tolerated in Phase 1 Study

News

Results of an early clinical trial found that a partial-onset seizure treatment, ADS-4101 (modified-release lacosamide) tablets, are safe and well-tolerated when compared to Vimpat, an approved but immediate-release version of the medication, ... Read more

April 28, 2017May 4, 2017

Fycompa Effective as Add-on Antiepileptic Drug in Patients with Tonic-Clonic Seizures, Data Suggests

News

Eisai recently presented data in Boston showing that the effect of its epilepsy treatment, Fycompa, and other antiepileptic drugs (AEDs) against primary generalized tonic-clonic seizures seems to be similarly positive in children and adults. The ... Read more

April 3, 2017April 3, 2017

First Epilepsy Clinical Trial Patients Implanted with Dose-delivering Prometra II Device

News

The first refractory epilepsy patients have been implanted with Prometra II programmable infusion pumps for a clinical trial of the dose-delivery devices, according to the product’s developers, Flowonix Medical and Cerebral Therapeutics. Dan ... Read more

March 6, 2017

Zogenix’s ZX008 Wins European Orphan Drug Designation to Treat Lennox-Gastaut Syndrome

News

The European Commission has designated Zogenix’s ZX008 (fenfluramine) as an orphan drug for the treatment of Lennox-Gastaut syndrome (LGS), a rare form of pediatric epilepsy. The designation follows a positive opinion ... Read more

February 27, 2017

Anti-epilepsy Medicine During Pregnancy Doesn’t Affect Newborns, Study Suggests

News

Children whose mothers took anti-epilepsy medicine during their pregnancy have no more health concerns than children whose mothers were untreated, according to a Danish study. The research, “Prenatal exposure to ... Read more

February 15, 2017

Participants in OB-GYN Clinical Trials Achieve Better Health Outcomes, Review Finds

News

Women participating in OB-GYN clinical trials experienced better outcomes in their health than those outside trials, regardless of whether the treatment is found to be effective in the trial, a ... Read more

January 20, 2017

New Guideline OKs Consideration of Functional MRI Prior to Epilepsy Surgery

News

The American Academy of Neurology has issued an evidence-based guideline that says physicians may consider using functional magnetic resonance imaging (fMRI) to map the memory and language functions of patients’ ... Read more

January 13, 2017January 13, 2017

Choke Point’ of Absence Seizures Reportedly Found, May Be Way of Preventing Them

News

Researchers at Stanford University School of Medicine say they’ve discovered the “choke point” of absence seizures in the brain, and that these seizures can be reduced, stopped, or even prevented with a technique ... Read more